ZYXI - Zynex Inc. (ZYXI) Q1 2023 Earnings Call Transcript
2023-04-29 14:49:03 ET
Zynex, Inc. (ZYXI)
Q1 2023 Earnings Conference Call
April 27, 2023 4:15 PM ET
Company Participants
Louisa Smith - Investor Relations
Thomas Sandgaard - Chairman, President and Chief Executive Officer
Anna Lucsok - Chief Operating Officer
Donald Gregg - Vice President, Zynex Monitoring Solutions
Daniel Moorhead - Chief Financial Officer
Conference Call Participants
Jeffrey Cohen - Ladenburg Thalmann
Adam Maeder - Piper Sandler
Yi Chen - H.C. Wainwright
Presentation
Operator
Good afternoon, ladies and gentlemen, and welcome to the Zynex First Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
I would now like to turn the conference over to Louisa Smith from the Gilmartin Group.
Louisa Smith
Thank you, Jason, and good afternoon, everyone. Earlier today, Zynex released financial results for the first quarter ending March 31, 2023. A copy of the press release is available on the company's website. Joining me on today's call are Thomas Sandgaard, Chairman, President and Chief Executive Officer; Dan Moorhead, Chief Financial Officer; Anna Lucsok, Chief Operating Officer; and Donald Gregg, President of Zynex Monitoring Solutions.
Before we begin, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's 2022 Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources or operating performance.
With that, I'll now turn the call over to Thomas.
Thomas Sandgaard
Thank you, Louisa, and good afternoon, everyone. Thank you for joining us today for the first quarter 2023 earnings call. We had another impressive period of growth, and we've now been profitable in 26 of the last 27 quarters. And we once again hit the highest number of prescriptions in the company's history, beating the records we previously said in the second, third and fourth quarters of 2022. Additionally, we were able to increase order numbers over Q4 despite the seasonal reset in deductibles that typical limits growth of orders in the beginning of the year.
Total revenue for the quarter was $42.2 million, a 36% increase over the same period in 2022, and we produced in earnings $0.04 per share. Our sales force is maintaining the exceptional trends in productivity and expanding our market share significantly each quarter, a testament to both the efficiency and our product efficacy.
Orders increased 61% year-over-year, and we believe that there is considerable runway for us to continue growing orders into the future. In the first quarter, we completed the latest in a series of stock buybacks and repurchased $3.4 million worth of common stock, bringing the total of repurchases in the last year to $30 million.
As we've stated before, I believe this to be a signal to our shareholders that we are incredibly confident in our management teams, the growth opportunities in both divisions and that we remain committed to creating shareholder value in the near and long term. In addition to the impressive results from our pain management division, our Monitoring Solutions division is making excellent strides in the development of our blood and fluid monitor and our laser-based pulse oximeter. Don Greg will provide further updates in his prepared remarks. But I'm pleased with the steps the growing team is taking to bring those game-changing products to market.
Monitoring Solutions has grown significantly over the past year. And after having acquired Kestrel Labs in December of 2021, we've been working diligently on clinical data collections and reaching regulatory milestones. Zynex continues to deliver consistent results and even with the investments in the monitoring division, our pain management business has been able to maintain profitability at the bottom line for the combined entity.
Our ability to execute operationally and strategically, while diversifying the business into compelling market opportunities is evidenced by the double-digit growth we've seen year after year. I look forward to announcing future catalysts and growth opportunities throughout 2023, and I'm thrilled with our performance to date.
With that, I will now turn the call over to Anna Lucsok, our Chief Operating Officer, for a more detailed business update on the pain management division.
Anna Lucsok
Thank you, Thomas. Zynex's pain management division had another impressive quarter marked by a sequential increase in order volumes over the fourth quarter and a 36% year-over-year increase in revenues. The growth that our sales team is delivering is consistent and profitable, and we believe there is significant room for continued expansion to reach full market penetration.
We ended the first quarter with approximately 460 sales reps and revenue per rep on an annualized basis was approximately $380,000, an increase of 24% over the first quarter of 2022. Sales reproductivity remains the primary area of emphasis in our sales organization. Our new hires are incorporating into the organization more quickly and the sales management structure we've implemented is optimizing performance across the board.
There are some lingering challenges related to the labor market, but we believe these to be improving over time, and we will remain committed to recruiting and retaining a high-quality sales and corporate team. We'll continue to expand into additional sales territories and expect to hit approximately 525 to 550 sales reps by year-end to capitalize the growing orders.
Our collections remained strong throughout the quarter, and we would like to reiterate that we have and we will continue to work with all payer types and insurance providers. We believe this to be a key differentiator between Zynex and some other competitors in the market as practitioners are able to prescribe our product to all patients in pain, not just a small cohort under specific insurance plan.
We process all orders that we receive and work directly with patients and their insurers to process coverage in each case. I look forward to another profitable year for the pain management division and updating you all on our market expansions on future calls.
I'll now ask Don Greg, President of Zynex Monitoring Solutions, to provide updates related to that business division.
Donald Gregg
Thank you, Anna. Zynex Monitoring Solutions is developing a strategic product portfolio and pipeline to address a nearly $4 billion market in the patient monitoring space, our initial products will cover hemodynamic monitoring, sepsis monitoring and laser-based pulse oximetry. As Thomas mentioned previously, our team has grown significantly in the last year and were invested substantially in the division as we make progress towards clinical and regulatory milestones.
Of the two product lines, we are actively developing the CM-1600 blood and fluid monitor is going to be the first in our go-to-market strategy as it's the furthest along in its regulatory pathway. The hemodynamic monitor is a noninvasive wireless blood and fluid monitor to be used in a hospital setting. The previous generation device, the CM-1500 has already received clearance from the FDA, and we've added a wireless capability to the CM 1600.
The CM-1600 was submitted to the FDA, and we are anticipating further details from the agency as we are currently engaged in an interactive review with them. As a reminder, Zynex is not contemplating any revenue from the monitoring division and its guidance for 2023. Additionally, in development are the NIKO or also known as the noninvasive pulse oximeter and the HEMOX pulse oximeter, both noninvasive laser technologies. We believe that this innovative technology will replace the less accurate LED-based legacy devices that are currently used today.
We are on track for NIKO submission to the FDA in Q4 2023 and actively running clinical trials. In addition to engineering and development advancements within the division, we are also involved in planning and rolling publishing numerous clinical trials to include hundreds of subjects across the country. We've seen encouraging results on product efficacy thus far and remain confident with the market opportunity for the disruptive technology.
As we publish further data, we will advise the investment community via press releases and on future quarterly calls. I'm excited to be a part of what should be a notable inflection point in the monitoring division over the next 18 to 24 months and look forward to leveraging our innovative technology in the market. I will now turn the call over to Dan Moorhead, Chief Financial Officer, for a more in-depth look at the financial performance for the quarter.
Daniel Moorhead
Thanks, Don. Please refer to our press release issued earlier today for a summary of our financial results for the first quarter of 2023. After commenting on the financial results, Thomas will review our guidance for 2023. Orders grew 61% year-over-year and net revenue grew 36% to $42.2 million from $31.1 million in 2022. Device revenue increased 78% to $11.9 million compared to $6.7 million in the first quarter last year.
Supplies revenue increased 24% year-over-year to $30.2 million from $24.4 million and gross margin was 78% in the first quarter. Sales and marketing expenses were $21.2 million in the first quarter of 2023 compared to $14.4 million in the same period in 2022. G&A expenses were $11.4 million in the first quarter of 2023 compared to $7.8 million last year. Approximately 20% of the increase in G&A is related to investments in our Monitoring Solutions division and related headcount to launch our new products. The remainder is primarily for back-office headcount related to order growth.
Tax expense as a percentage was a 2% effective rate for the quarter due to other income of $1.4 million. Net income grew 14% year-over-year to $1.6 million and produced $0.04 per diluted share in the first quarter of 2023. We ended the quarter with $16.8 million in cash. Cash flow from operations in the quarter increased 10% year-over-year to $1.9 million.
I'll now turn the call back over to Tom.
Thomas Sandgaard
Thank you, Dan. We grew orders in the fourth quarter of last year by 48% year-over-year. It increased to 61% in the first quarter of the year. And here in the beginning of the second quarter, we've already had a strong start in terms of orders and expect to post our fifth consecutive record quarter. With the continued growth in orders in the second quarter of 2023, we expect total revenue between $43.5 million and $45.5 million, which is approximately 21% greater than the second quarter of 2022, and we expect to see earnings per share between $0.03 and $0.07.
As for our 2023 outlook, we are reiterating our initial guidance and expect total revenue to be in the range of $180 million to $200 million, representing growth of approximately 21% over 2022 and earnings per share of approximately $0.40 to $0.50.
With that, operator, please open the call up for questions.
Question-and-Answer Session
Operator
We will now begin the question-and-answer session. [Operator Instructions] Our first question comes from Jeffrey Cohen from Ladenburg Thalmann.
Jeffrey Cohen
So congrats on the quarter, it looks very strong. Just a couple of questions from me. And I guess, firstly, are you still feeling pretty optimistic on 1600 and time line to approval. Are we still hopeful about back half of the year or closer?
Donald Gregg
This is Don. We are definitely feeling confident. As I mentioned, we're in the interactive review with the FDA. So it's been a bit of a back and forth. We -- in those discussions, have had an opportunity to ensure that the FDA feels comfortable with the device and the technology. And so I'll reiterate our plans at this point are the same.
Jeffrey Cohen
Maybe hypothesize with us how you're thinking about commercial strategies and direct non-direct from a commercial standpoint into next year?
Donald Gregg
Yes. So I think we mentioned before that we would have a direct and an indirect sales team. We will grow that slowly as we enter the market. This is a brand-new market essentially, in which requires some market development. So we have some placement of devices that we will need to do and certainly prove out the technology to clinicians, et cetera. As we get closer to our products on the NIKO non-invasive co-oximeter -- that's a fairly defined market. And so our strategy there is slightly different. And so as I had mentioned previously, we will be submitting to the FDA later in the year on that device. And we're actively in running clinical trials here between now and the back half of the year.
Jeffrey Cohen
And HEMOx, will that also get filed submitted this year.
Donald Gregg
That will not be submitted later this year, but we are working on the technology. So the laser technology applies to both the pulse or oximeter and to HEMOX. And HEMOX will bring different technology and parameters to the market, meaning that you'll have total hemoglobin and other parameters like that with HEMOX.
Jeffrey Cohen
And I guess a question for Anna as far as the sales force and growth. It sounds like it will be linear throughout the year, kind of on par with Q1? Or is there orders coming through earlier or later?
Anna Lucsok
The growth will be in line with Q1. We'll continue to grow our orders throughout the year.
Thomas Sandgaard
And the number of sales reps.
Donald Gregg
Yes. This will be fairly linear, Jeff.
Jeffrey Cohen
And then lastly, congrats on the buybacks at $8.82 on average. What's the share count now? Is it I see 37.44 -- is that diluted currently? And the buybacks have concluded with none open today?
Daniel Moorhead
Diluted for the -- while diluted outstanding was $37.4 million. The other figure will be in the press release as well, the actual number of shares and in the Q. But yes, we do not currently have a buyback that is open right now.
Operator
The next question comes from Adam Maeder from Piper Sandler.
Adam Maeder
Congrats on a nice start to the year. I wanted to start with the sales force update. If I heard correctly, the new target is 525 to 550 by year-end. I think before you were aiming closer to 550. And I think you're at 460 exiting Q1. So just curious, are you seeing is something kind of changed from a hiring environment standpoint? Did you see any attrition in the quarter? And then maybe just also talk about level of confidence in delivering against the top line outlook and any dependence there kind of hitting the headcount target.
Anna Lucsok
Yes. So there are not a lot of changes in the hiring market. The hiring market is improving as we're seeing it. But obviously, we can't speak with confidence on how the remainder of the year is going to go. We are a lot quicker with exiting underperformers out of the organization, and we'll continue focusing on that throughout the year.
Adam Maeder
Okay. So nothing, I guess, as it relates to Q1, it wasn't a -- there's no issue with attrition of reps. It was maybe just hired a little bit more slowly than expected. Is that a fair conclusion?
Daniel Moorhead
Timing a little bit to Adam. Some people will start right after the end of the quarter. And throughout the year, obviously, a quarter cutoff, it can be a little misleading at times. But we've seen a pretty good hiring cadence and had a pretty good group coming in April as well. So I think we're pretty comfortable with the numbers. And we gave a range, the 525 to 550, but we think that's very achievable.
Adam Maeder
And then I guess for the follow-up, I wanted to ask about NIKO. And if I heard correctly, Q4 '23 FDA submission, anything you guys can share at this point in terms of the clinical performance or learnings from the clinical studies that you've run, how do we think about likelihood of approval or any potential clinical risk? And then I have one follow-up.
Donald Gregg
Sure. This is Don. I'll take that question. We have been running a bench study, and those are internal studies at this point in time. We have a clinical study that's starting here in May at a clinical trial site in the pulse oximetry market, there's an FDA guidance document that pretty clearly outlined that you got to run certain human studies on your hypoxia calibration and verification. And so we're starting all of those. The performance of the device is significantly more accurate at this point than what we were expecting. We're seeing ranges of accuracy higher than legacy devices that you see on the market today based on LED technology. And so we believe that -- our submission is definitely on track for Q4. We're trying to hit the earlier part of Q4 at this point in time, but certainly given guidance that it's going to be submitted to the FDA in the Q4 time frame.
Adam Maeder
And then maybe just one last one for me, and I'll jump back in queue. It relates to just the guidance range, the full year EPS guidance. I was hoping you could just bridge us a little bit to that range. It looks like it implies a little bit of a healthy ramp in the back half of the year to kind of get to the bottom or the midpoint. So just broad strokes, Dan, can you just talk through kind of the cadence of spend and I guess any color on the top line cadence as well? Congrats again on the start to the year.
Daniel Moorhead
Yes. No, I think, again, top line, we're tracking orders have been strong, 51%. We expect that to continue. On the spend, I think it will continue to grow, obviously, on the sales and marketing line as we grow the sales territory managers and other pieces there, commissions and other things that are variable based on number of orders. And then on the G&A side, most of that is going to be around the DMS side. But the ramp is going to be similar to what it was last year. Last year, the majority -- well over the majority was in the second half of the year and that will continue this year. So I think the $0.04 we did in Q1, I think consensus for Q2, Q3 and Q4 are similar with your -- with the numbers you guys have out there and that gives us right there.
Operator
Our next question comes from Yi Chen from H.C. Wainwright.
Yi Chen
Could you comment on whether you observed that the productivity of the sales team increase proportionately to the increase in orders.
Thomas Sandgaard
So we said the increase in sales productivity was up about 24% and orders were up 61%. You just got to remember, orders will recognize revenue over a period of -- we generally say 6 to 9 months, so there's always going to be a lag there. So we were pleased with the revenue increase, obviously, and the order increase, but the revenue obviously means we're turning that into cash and growing the top line.
Yi Chen
Okay. And could you discuss in your opinion, what are the key factors that would ensure a successful launch trajectory for the fluid monitor?
Donald Gregg
Yes. This is Don again. I think that for us, adoption in the market by key clinical opinion leaders is very important. The way that our technology works is quite different than other monitors in that space at this point in time. Significantly, products in that area are somewhat, I would call, more invasive or minimally invasive, and ours is certainly based on noninvasive technology.
We will ensure that we communicate effectively to key opinion leaders. We've been doing that throughout the development and have many of them on board with us to understand the technology. We also run a number of clinical trials in several different ways to demonstrate and exercise the effectiveness of the device. And so that is a key entry. As I mentioned previously on the call that this is a new market that requires a lot of market development and adoption of this technology is very important from a clinical standpoint.
Operator
This concludes our question-and-answer session. I would like to turn the conference back over to Thomas Sandgaard for any closing remarks.
Thomas Sandgaard
Yes. Thank you for joining us today. We are pleased with our performance this quarter and the consistent growth our team is delivering. We look forward to leveraging that momentum throughout the rest of the year and to speaking to you at our upcoming investor events. We appreciate your time and interest in Zynex. Have a great day.
Operator
Conference has now concluded. Thank you for attending today's presentation. You may now disconnect.
For further details see:
Zynex, Inc. (ZYXI) Q1 2023 Earnings Call Transcript